Test of a biologic for active spondyloarthritis
Treatments studied
Part of Bones, joints & muscles clinical trials.
This trial studies whether adding a biologic medicine (targeted therapy) can help people with active spondyloarthritis when standard anti-inflammatory pain medicines (NSAIDs) have not worked well enough. It focuses on people with ongoing symptoms despite trying at least two NSAIDs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have spondyloarthritis that matches the ASAS criteria (a standard set of diagnosis rules doctors use).
- Your doctor expects you may need a biologic medicine because at least two NSAIDs did not control your symptoms.
- Your disease is currently active, with a BASDAI score higher than 4 (a symptom/activity score).
- Your main problem involves the spine or pelvis (axial symptoms are predominant), not mainly other body areas.
- You have not already taken a biologic medicine before.
- You do not have any medical reason that would make biologic treatment unsafe for you (no contraindications).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with inflammatory arthritis (rheumatoid arthritis or spondyloarthritis) to learn more about how well biologic or targeted therapies work. If you have tried standard treatments without enough relief, this may help researchers improve future care.
This study looks at your gut bacteria (from a stool sample) to see whether it can predict how well you will respond to biologic medicines for spondyloarthritis. It may help doctors choose the most effective treatment for future patients.
This study looks at how a body signal called IL-23 may drive inflammation in spondyloarthritis (including joints) using samples from your care. It may help researchers identify which body cells and targets are involved, and how treatments could work better for active disease.
This trial tests a new oral medication called LNK01001 for adults with active ankylosing spondylitis. It aims to reduce pain, stiffness, and inflammation when standard NSAID treatments no longer help.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
This trial tests whether combining two biologic medications (adalimumab and secukinumab) can better relieve symptoms of ankylosing spondylitis, a type of arthritis that affects the spine. It may help if you have not responded well to standard nonsteroidal anti-inflammatory drugs (NSAIDs) and you have active disease.
Hear when a new Spondylarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.